The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice

Cancer Chemother Pharmacol. 1990;25(5):377-9. doi: 10.1007/BF00686242.

Abstract

Binary combinations of cisplatin and the 5-HT3 antagonist, BRL 43694, have been used to treat both conventional mice bearing either L1210 leukaemia or ADJ/PC6 plasmacytoma and nude mice xenografted with a human ovarian carcinoma (HX/110). In no case was there evidence for antagonism by the antiemetic of the antitumour properties of cisplatin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cisplatin / administration & dosage
  • Cisplatin / therapeutic use*
  • Drug Interactions
  • Drug Therapy, Combination
  • Granisetron
  • Indazoles / administration & dosage
  • Indazoles / therapeutic use*
  • Leukemia L1210 / drug therapy
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Neoplasm Transplantation
  • Neoplasms, Experimental / drug therapy*
  • Plasmacytoma / drug therapy
  • Pyrazoles / therapeutic use*
  • Serotonin Antagonists / administration & dosage
  • Serotonin Antagonists / therapeutic use*

Substances

  • Indazoles
  • Pyrazoles
  • Serotonin Antagonists
  • Cisplatin
  • Granisetron